Did you know that many prostate cancers grow so slowly that they may never require treatment during a patient’s lifetime? Active surveillance represents a deliberate medical strategy where healthcare providers monitor low-risk prostate cancer rather than immediately treating it.
The decision between active surveillance and immediate treatment depends on several factors:
- Specific tumour characteristics
- PSA levels (a protein produced by the prostate that can indicate potential problems when elevated)
- Gleason scores, a grading system that indicates how aggressive the cancer cells appear
- Individual patient factors that your urologist evaluates through comprehensive testing
Your doctor can help determine an appropriate approach based on your specific situation and risk factors.
Understanding Active Surveillance
Active surveillance differs from watchful waiting. Watchful waiting involves minimal testing and treats symptoms only when they appear, such as difficulty urinating or bone pain. Active surveillance employs regular, structured monitoring with predetermined intervention triggers. This approach may be suitable for men with low-risk prostate cancer characterised by PSA levels below a certain threshold, Gleason scores indicating lower-grade disease, and cancer confined to a small area of the prostate.
The protocol involves:
- Regular PSA blood tests periodically
- Digital rectal examinations, where the doctor feels the prostate through the rectal wall to check for abnormalities, are performed at regular intervals
- Repeat prostate biopsies or where the doctor removes small tissue samples for examination at specific intervals
Multiparametric MRI imaging is a detailed scans that create pictures of the prostate to assess cancer location and size, and is often incorporated to support monitoring and reduce the frequency of repeat biopsies. These combined assessments track any changes in cancer behaviour that might signal the need for treatment.
Your urologist establishes intervention thresholds based on your initial diagnosis and individual risk factors. PSA doubling time (how quickly PSA levels increase, which may indicate cancer growth), changes in Gleason score on repeat biopsy, or increased tumour volume on imaging typically trigger discussions about starting treatment. This systematic approach helps monitor cancer progression.
Medical Evidence Supporting Safety
Long-term studies demonstrate that carefully selected patients on active surveillance achieve outcomes comparable to those who choose immediate treatment. The ProtecT trial followed men for over a decade and found no difference in prostate cancer-specific survival between those who chose active surveillance versus immediate treatment for low-risk disease. Similar results emerged from cohorts at Johns Hopkins, the University of Toronto, and multiple European centres.
Active surveillance protocols have evolved to incorporate genomic testing, which analyses your tumour’s genetic makeup to predict how it might behave, and imaging techniques. These tools help identify which cancers belong in the low-risk category. Genomic tests analyse tumour tissue to predict aggressive behaviour. Multiparametric MRI (a scan that creates detailed images of the prostate) can detect cancers that standard biopsies might miss. This enhanced risk stratification can improve patient selection for active surveillance.
Studies show that anxiety about living with untreated cancer typically decreases after the first year on surveillance. Patients gain confidence in the monitoring process over time. Support groups and counselling services help address these concerns when they arise.
Monitoring Protocols and Frequency
Standard active surveillance protocols begin with confirmatory testing within the first year. This often includes a repeat biopsy to ensure the initial diagnosis accurately represents the cancer’s extent and grade. During a biopsy, the doctor takes small tissue samples from the prostate using a thin needle. Some centres perform MRI-guided biopsies to sample suspicious areas.
PSA monitoring follows a regular schedule, typically every few months for the first couple of years, then less frequently if values remain stable. PSA is a blood test that measures prostate-specific antigen, a protein produced by the prostate. Your urologist tracks not just the absolute PSA value but also the rate of change over time. A PSA doubling time of less than a few years often prompts closer evaluation or consideration of treatment.
Repeat biopsies may be recommended at predetermined intervals, though the exact timing varies between institutions. Many programmes perform biopsies at regular intervals over several years, then every few years thereafter. MRI imaging may replace some biopsies if it shows no progression.
Digital rectal examinations complement other monitoring tools by detecting physical changes in the prostate. During this examination, the doctor uses a gloved finger to feel the prostate through the rectal wall. These examinations can identify nodules or hardening that may warrant further investigation.
Identifying Suitable Candidates
Suitable candidates for active surveillance have very low-risk or low-risk prostate cancer according to established criteria. Very low-risk disease involves PSA density (a measure of how much PSA is present relative to prostate size) below a certain threshold, a small number of positive biopsy cores (samples showing cancer), and minimal core involvement by cancer. Low-risk disease includes relatively low PSA levels, a Gleason score of 6, and clinical stage T1c or T2a (classifications describing the size and extent of the tumour).
Age and overall health influence surveillance decisions. Younger men with longer life expectancies face more years of potential cancer progression. Conversely, older men or those with health conditions may benefit from avoiding treatment side effects when their cancer poses minimal immediate threat. A healthcare professional can discuss targets and recommendations tailored to specific risk factors, including age, overall health, and personal circumstances.
Patient preference plays a vital role after all options have been understood. Some men find comfort in removing the cancer immediately. Others prefer avoiding treatment side effects as long as safely possible. A urologist can help weigh these personal factors against medical recommendations to find an approach that suits individual needs.
Genomic testing refines risk assessment beyond traditional clinical parameters. Tests like Oncotype DX, Prolaris, or Decipher (diagnostic tools that analyse genetic patterns in tumour tissue) examine genetic patterns to predict how aggressively the cancer might behave. These results can help identify cancers that appear low-risk by standard criteria but may have aggressive potential, guiding treatment decisions tailored to individual situations.
Risks and Limitations
Active surveillance carries the risk of disease progression during monitoring. This means the cancer may grow or spread. Protocols aim to detect progression before it becomes incurable. However, some patients develop metastatic disease, or the cancer that has spread to other parts of the body, despite appropriate monitoring. This risk appears highest in patients who don’t follow recommended testing schedules or those with higher-volume disease at diagnosis.
Repeat biopsies (procedures where the doctor removes small tissue samples for examination) carry procedural risks. These include bleeding, infection, and temporary urinary symptoms. Each biopsy has a small risk of severe disease requiring hospitalisation. Current MRI-guided biopsies may reduce the total number of procedures needed while improving detection accuracy.
Some patients experience ongoing anxiety about harbouring untreated cancer. This psychological burden can affect the quality of life for specific individuals, even when medical evidence supports the safety of continued surveillance. Regular communication with your healthcare team helps address these concerns as they arise.
The need for frequent medical appointments and tests creates logistical challenges for some patients. Travel requirements, work schedules, and healthcare costs influence the feasibility of maintaining surveillance protocols. These practical considerations factor into initial treatment decisions.
When to Transition to Treatment
Clear indicators for transitioning from surveillance to active treatment include:
- Grade progression (when cancer cells become more abnormal) on repeat biopsy
- Significant increase in tumour volume
- Rapid PSA rise
- Patient preference
Grade progression, particularly to Gleason score seven or higher (a system that measures how abnormal cancer cells look under a microscope), represents a trigger for initiating treatment.
PSA kinetics is the pattern of PSA levels over time that can provide valuable information about progression. While no absolute PSA threshold mandates treatment, a doubling time under a specific timeframe or velocity exceeding a certain rate warrants close evaluation. Your urologist considers PSA changes alongside other clinical factors rather than making decisions based solely on PSA.
MRI findings increasingly influence treatment timing. New lesions (areas of abnormal tissue), growing existing lesions, or development of extracapsular extension, which means the cancer is spreading beyond the prostate.
Patient-initiated transitions occur when anxiety about untreated cancer outweighs concerns about treatment side effects. This decision remains valid even without medical progression indicators. Open discussion with your urologist so you can understand the implications of choosing treatment at any point during surveillance.
Preparation Steps for Active Surveillance
Before Starting Surveillance:
- Confirm your cancer meets low-risk criteria through comprehensive staging (a process where doctors determine the extent and severity of the cancer).
- Consider a confirmatory MRI (a detailed imaging scan) or repeat biopsy (where a doctor removes a small tissue sample to examine under a microscope) for accurate initial assessment.
- Discuss genomic testing options or the tests that analyse your cancer’s genetic makeup to refine risk stratification. It is the process of determining how likely your cancer is to grow or spread.
- Work with your urologist to develop a monitoring schedule.
- Understand specific triggers that may prompt a treatment recommendation.
Maintaining Surveillance:
- Keep all scheduled appointments for PSA tests and examinations.
- Report new urinary symptoms such as difficulty urinating, blood in urine, or increased urgency or changes promptly.
- Maintain a healthy lifestyle with regular exercise and balanced nutrition.
- Join support groups if anxiety about surveillance affects daily life.
- Keep records of all test results for tracking trends over time.
When to Seek Professional Help
- PSA rising faster than expected between scheduled appointments
- New or worsening urinary symptoms, such as needing to urinate more frequently, feeling a sudden, urgent need to urinate, or noticing blood in your urine
- Bone pain or unexplained weight loss
- Difficulty maintaining scheduled surveillance appointments
- Persistent anxiety affecting sleep or daily activities
- Questions about incorporating current monitoring technologies
- Interest in second opinions about surveillance appropriateness
- Family history changes that may affect cancer risk assessment
Commonly Asked Questions
How long can I safely remain on active surveillance?
Many men remain under surveillance for a significant period without requiring treatment. The duration depends on individual cancer behaviour and patient preference. Regular monitoring for timely intervention if cancer characteristics change. Some men continue surveillance indefinitely if their cancer remains stable and they maintain good overall health.
Will delaying treatment reduce my chances if I eventually need it?
Men who progress on surveillance and receive deferred treatment can achieve similar cure rates to those treated immediately. The approach lies in adhering to monitoring protocols and treating promptly when progression indicators appear. Your urologist monitors carefully to intervene before the window for curative treatment closes.
Can I travel extensively while on active surveillance?
You can travel with proper planning. Schedule PSA tests around your travel plans. Arrange testing at your destination for extended trips. Many laboratories worldwide can perform PSA testing with results sent to your urologist. Maintain flexibility in travel plans around scheduled biopsies (procedures where the doctor removes small tissue samples for examination) or imaging studies that require your local facility.
What happens if I miss surveillance appointments?
Missing occasional appointments rarely causes problems, but consistent monitoring remains essential for safety. Contact your urologist to reschedule missed appointments promptly. Prolonged gaps in monitoring increase the risk of missing progression signals. If maintaining the schedule becomes difficult, discuss modified protocols or alternative management strategies with your healthcare team.
How do I explain active surveillance to family members who think I should treat the cancer immediately?
Share educational materials from your urologist that explain that active surveillance is active medical management, not neglect. Treatment remains available if needed. Consider bringing concerned family members to appointments where your urologist can address their questions directly. Helping loved ones understand your decision can provide valuable emotional support.
Conclusion
Active surveillance offers effective management for men with low-risk prostate cancer. Success requires consistent monitoring and understanding progression indicators. Treatment remains available when cancer characteristics change while avoiding unnecessary intervention for stable disease.
If you’re experiencing symptoms like a weak urinary stream, frequent urination, or difficulty starting urination, consult a urologist to evaluate your prostate health and discuss whether active surveillance may be appropriate for your situation.
